Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015)

Reference

• Massoulie J, Pezzementi L, Bon S, et al. Molecular and cellular biology of the cholinesterases. Prog Neurolbiol 1993;41:31–39.
   PubMed Web of Science ®Google Scholar
• Antosiewics J, Gibson M, Lee I, et al. Acetylcholinesterase: Diffusional encounter rate constants for dumbbell models of ligands. Biophys J 1995;68:62–68.
   PubMed Web of Science ®Google Scholar
• Colovic, MB, Kristic DZ, Vasic VM, et al. Acetylcholinesterase Inhibitors: Pharmacology and Toxicology. Curr Neuropharmacol 2013;11:315–335.
   PubMed Web of Science ®Google Scholar
• Johnson G,Moore SW. The adhesion function on the acetylcholinesterase is located at the peripheral anionic site. Biochem Bioph Res Co 1999;258:758–762.
   PubMed Web of Science ®Google Scholar
• Jbilo O, Bartels CF, Chatonnet A, et al. Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA. Toxicon 1994;11:1445–1457.
   Web of Science ®Google Scholar
• Fabrichny IP, Leone P, Sulzenbacher G, et al. Structural Analysis of the Synaptic Protein Neuroligin and Its β−Neurexin Complex: Determinants for Folding and Cell Adhesion. Neuron 2007;56:979–991.
   PubMed Web of Science ®Google Scholar
• Samadi A, de la Fuente Revenga M, Perez C, et al. Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: New dual AChE inhibitors as potential drugs for the treatment of Alzheimer’s disease. Eur J Med Chem 2013;67:64–74.
   PubMed Web of Science ®Google Scholar
• Nachon F, Carletti E, Renard PY, et al. Crystal Structures of human cholinesterase in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer’s drug targeting acetyl- and butyryl-cholinesterase. Biochem J 2013;453:393–399.
   PubMed Web of Science ®Google Scholar
• Silman I, Sussman JL. Acetylcholinesterase: how is structure related to function? Chem Biol Interact 2008;175:3–10.
   PubMed Web of Science ®Google Scholar
• Quinn DM. Acetylcholinesterase: enzyme structure, reaction dynamics, and virtual transition states. Chem Rev 1987;87:955–979.
   Web of Science ®Google Scholar
• van der Kamp MW, Mulholland AJ. Computational enzymology: insight into biological catalysts from modeling. Nat Prod Rep 2008;25:1001–1014.
   PubMed Web of Science ®Google Scholar
• Silva D, Marco-Contelles J, Chioua M, et al. Synthesis, Pharmacological Assessment, and Molecular Modeling of Acetylcholinesterase/Butyrlcholinesterase Inhibitors: Effect against Amyloid-β-Induced Neurotoxicity. ACS Chem Neurosci 2013;4:547–565.
   PubMed Web of Science ®Google Scholar
• Cheung J, Rudolph M, Burshteyn F, et al. Structures of Human Acetylcholinesterase in Complex with Pharmacologically Important Ligands. J Med Chem 2012;55:10282–10286.
   PubMed Web of Science ®Google Scholar
• Bartolucci C, Stojan J, Yu QS, et al. Kinetics of Torpedo californica acetylcholinesterase inhibition by bisnorcymserine and crystal structure of the complex with its leaving group. Biochem J 2012;444:269–277.
   PubMed Web of Science ®Google Scholar
• Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003;4:131–138.
   PubMed Web of Science ®Google Scholar
• Branduardi D, Luigi Gervasio F, Cavalli A, et al. The role of the peripheral anionic site and cation-π interactions in the ligand penetration of the human AChE gorge. J Am Chem Soc 2005;127:9147–9155.
   PubMed Web of Science ®Google Scholar
• Muir JL. Acetylcholine, Aging, and Alzheimer’s Disease. Pharmacol Biochem Be 1997;56:687–96.
   PubMed Web of Science ®Google Scholar
• Goedert M, Spillantini MG. A Century of Alzheimer’s Disease. Science 2006;314:777–781.
   PubMed Web of Science ®Google Scholar
• Pákáski M, Kálmán J. Interactions between the amyloid and cholinergic mechanisms in Alzheimer’s disease. Neurochem Int 2008;53:103–111.
   PubMed Web of Science ®Google Scholar
• Castro A, Martinez, A. Targeting Beta-Amyloid Pathogenesis Through Acetylcholinesterase Inhibitors. Curr Pharm Design 2006;12:4377–4387.
   PubMed Web of Science ®Google Scholar
• Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci 2016;17:22–35.
   PubMed Web of Science ®Google Scholar
• Padurariu M, Ciobica A, Lefter R, et al. The oxidative stress hypothesis in Alzheimer’s disease. Psychiat Danub 2013;25:401–409.
   PubMed Web of Science ®Google Scholar
• Inestrosa NC, Alvarez A, Pérez CA, et al. Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer’s Fibrils: Possible Roe of the Peripheral Site of the Enzyme. Neuron 1996;16:881–891.
   PubMed Web of Science ®Google Scholar
• Schneider L S. A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer’s disease. Dialog in Clin Neurosci 2000;2:111–128.
   PubMedGoogle Scholar
• Meriggioli MN. Myasthenia gravis with anti-acetylcholine receptor antibodies. Front Neurol Neurosci 2009;26:94–108.
   PubMedGoogle Scholar
• Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis (Review). Cochrane Database Syst Rev 2014;10:1–20.
   Google Scholar
• Pagano G, Rengo G, Pasqualetti G, et al. Cholinesterase inhibitors for Parkinson’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2015;86:767–773.
   PubMed Web of Science ®Google Scholar
• Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev 2012;3:1–68.
   Google Scholar
• Aarsland D, Mosimann U P, McKeith I G. Role of Cholinesterase Inhibitors in Parkinson’s Disease and Dementia with Lewy Bodies. J Geriatr Psychiatry Neurol 2004;17:164–171.
   PubMed Web of Science ®Google Scholar
• Kuca K, Jun D, Musilek K, et al. Prophylaxis and Post-exposure Treatment of Intoxications Caused by Nerve Agents and Organophosphorus Pesticides. Mini-Rev Med Chem 2013;13;2102–15.
   PubMed Web of Science ®Google Scholar
• Čolović M B, Krstić D Z, Lazarević-Pašti T D, et al. Acetylcholinesterase Inhibitors: Pharmacology and Toxicology. Curr Neuropharm 2013;11:315–335.
   PubMed Web of Science ®Google Scholar
• Eyer PA, Worek F. Oximes. Chemical Warfare Agents: Toxicology and Treatment 2007; 305–329.
   Google Scholar
• Jokanovic M, Prostran M. Pyridinium oximes as cholinesterase reactivators. Structure-activity relationship and efficacy in the treatment of poisoning with organophosphorus compounds. Curr Med Chem 2009;16:2177–2188.
   PubMed Web of Science ®Google Scholar
• Kalász H, Nurulain SM, Veress G, et al. Mini review on blood-brain barrier penetration of pyridinium aldoximes. J App Toxicol 2015;35:116–123.
   PubMed Web of Science ®Google Scholar
• Voicu V, Rădulescu FŞ, Medvedovici A. Toxicological considerations of acetylcholinesterase reactivators. Expert Opin Drug Metab Toxicol 2013;9:31–50.
   PubMed Web of Science ®Google Scholar
• Kalász H, Nurulain SM, Veress G, et al. Mini review on blood-brain barrier penetration of pyridinium aldoximes. J App Toxicol 2015;35:116–123.
   PubMed Web of Science ®Google Scholar
• de los Rios C. Cholinesterase inhibitors: a patent review (2007-2011). Expert Opin Ther Patents 2012;22:853–869.
   Google Scholar
• Pohanka M. Acetylcholinesterase inhibitors: a patent review (2008-present). Expert Opin Ther Patents 2012;22:871–886.
   PubMed Web of Science ®Google Scholar
• Lopez-Arrieta JM, Schneider L. Metrifonate for Alzheimer’s disease. Cochrane Database Syst Rev 2006;2:1–40.
   Google Scholar
• Crismon ML. Tacrine: first drug approved for Alzheimer’s disease. Ann Pharmacother 1994;28:744–751.
   PubMed Web of Science ®Google Scholar
• Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 1994;271:992–998.
   PubMed Web of Science ®Google Scholar
• Romero A, Cacabelos R, Oset-Gasque MJ, et al. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer’s disease. Bioorg Med Chem Lett 2013;23:1916–1922.
   PubMed Web of Science ®Google Scholar
• Inestrosa NC, Alvarez A, Perez CA, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron 1996;16:881–891.
   PubMed Web of Science ®Google Scholar
• Alvarez A, Alarcon R, Opazo C, et al. Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer’s fibrils. J Neurosci 1998;18:3213–3223.
   PubMed Web of Science ®Google Scholar
• Dinamarca MC, Arrazola M, Toledo E, et al. Release of acetylcholinesterase (AChE) from beta-amyloid plaques assemblies improves the spatial memory impairments in APP-transgenic mice. Chem-Biol Interact 2008;175:142–149.
   PubMed Web of Science ®Google Scholar
• Chitra L, Kumar CR, Basha HM, et al. Interaction of metal chelators with different molecular forms of acetylcholinesterase and its significance in Alzheimer’s disease treatment. Proteins 2013;81:1179–1191.
   PubMed Web of Science ®Google Scholar
• Univ Guangxi Chinese Medicine. 9-amino substituted pyrido acridine derivative, preparation method and uses thereof. CN104327075; 2014.
   Google Scholar
• Sugimoto H, Ogura H, Arai Y, et al. Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn J Pharmacol 2002;89:7–20.
   PubMedGoogle Scholar
• Cheng X. Novel derivatives of donepezil. US2015225343; 2015.
   Google Scholar
• INSA. Oxidisable pyridine derivatives, their preparation and use as anti-Alzheimer agents. WO2014114742; 2014.
   Google Scholar
• INSA. New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-Alzheimer agents. WO2006103120;2006.
   Google Scholar
• Sramek JJ, Frackiewicz EJ, Cutler NR. Review of the acetylcholinesterase inhibitor galanthamine. Expert Opin Inv Drug 2000;9:2393–2402.
   PubMed Web of Science ®Google Scholar
• Marco-Contelles J, Carreiras MC, Rodriguez C, et al. Chem Rev, 2006;106:116–133..
   PubMed Web of Science ®Google Scholar
• Greenblatt HM, Kryger G, Lewis T, et al. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett 1999;463:321–326.
   PubMed Web of Science ®Google Scholar
• Univ East China Science & Tech., Galantamine analogue and application thereof. CN104860955; 2015.
   Google Scholar
• Liu J-S, Zhu Y-L, Yu C-M, et al. The structures of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity. Can J Chemistry 1986;64:837–839.
   Web of Science ®Google Scholar
• Bai DL, Tang XC, He XC. Huperzine A, a potential therapeutic agent for treatment of Alzheimer’s disease. Curr Med Chem 2000;7:355–374.
   PubMed Web of Science ®Google Scholar
• Moe Tun KM, Wustmann DJ, Herzon SB. A robust and scalable synthesis of the potent neuroprotective agent (–)-huperzine A. Chem Sci 2011;2:2251–2253.
   Web of Science ®Google Scholar
• Insero Health Inc. Conjugates of huperzine and analogs thereof. US20150191430;2015.
   Google Scholar
• Takano S, Ogasawara K. Alkloids of the Calabar Bean. The Alkaloids: Chemistry and Pharmacology 1989;36:225–251.
   Google Scholar
• Farlow M, Anand R, Messina J Jr, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur Neurol 2000;44:236–241.
   PubMed Web of Science ®Google Scholar
• Imbimbo BP. Pharmacodynamic tolerability relationships of cholinesterase inhibitors for Alzheimer’s disease. CNS Drugs 2001;15:375–390.
   PubMed Web of Science ®Google Scholar
• Lefevre G, Pommier F, Sedek G, et al. Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects. J Clin Pharmacol 2008;48:246–252.
   PubMed Web of Science ®Google Scholar
• Teikoku Pharma USA Inc. Rivastigmine transdermal compositions and methods of using the same. TW201603835; 2016.
   Google Scholar
• Noven Pharmaceuticals, Inc. Silicone-containing acrylic polymers for transdermal drug delivery compositions. US20160030362;2016.
   Google Scholar
• Bolognesi ML, Bartolini M, Cavalli A, et al. Design, synthesis and biological evaluation of conformationally restricted rivastigmine analogues. J Med Chem 2004;47:5945–5952.
   PubMed Web of Science ®Google Scholar
• Chaudhaery SS, Roy KK, Shakya N, et al. Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology. J Med Chem 2010;53:6490–6505.
   PubMed Web of Science ®Google Scholar
• Council of Scientific and Industrial Research. Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors. WO2006070394;2006.
   Google Scholar
• Roy KK, Tota S, Tripathi T, et al. Lead optimization studies towards the discovery of novel carbamates as potent AChE inhibitors for the potential treatment of Alzheimer’s disease. Bioorg Med Chem 2012;20:6313–6320.
   PubMed Web of Science ®Google Scholar
• Council of Scientific and Industrial Research. Substituted 1, 2, 3, 4-tetrahydroquinolin-7-yl carbamates as acetylcholinesterase inhibitors for treatment of Alzheimer’s disease. US20130324573;2013.
   Google Scholar
• Cavalli A, Bolognesi, ML, Minarini A, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008;51:347–372.
   PubMed Web of Science ®Google Scholar
• Bajda M, Guzior N, Ignasik M, et al. Multi-target-directed ligands in Alzheimer’s disease treatment. Curr Med Chem 2011;18:4949–4975.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang H, Chen HZ. AChE inhibition-based multi-target directed ligands, a novel pharmacological approach for the symptomatic and disease-modifying therapy of Alzheimer’s disease. Curr Neuropharmacol 2016;14:364–375.
   PubMed Web of Science ®Google Scholar
• Kozurkova M, Hamulakova S, Gazova Z, et al. Cholinesterase, anti-amyloid aggregation and neuroprotective properties. Pharmaceuticals 2011;4:382–418.
   Google Scholar
• Munoz-Ruiz P, Rubio L, Garcia-Palomero E, et al. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer’s disease. J Med Chem 2005;48:7223–7233.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Franco MI, Fernandez-Bachiller MI, Perez C, et al. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J Med Chem 2006;49:459–462.
   PubMed Web of Science ®Google Scholar
• Spuch C, Antequera D, Fernandez-Bachiller MI, et al. A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer’s disease. Neurotox Res 2010;17:421–431.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Ishihara Y, Kuntz ID. Docking analysis of a series of benzylamino acetylcholinesterase inhibitors with a phthalimide, benzoyl, or indanone moiety. J Med Chem 1994;37:3141–3153.
   PubMed Web of Science ®Google Scholar
• Centrum Medyczne. Novel hybrid cholinesterase inhibitors. US20140080860;2014.
   Google Scholar
• Univ China Pharma. Tacrine-beta-carboline conjoined multifunction cholinesterase inhibitor. CN104003987;2014.
   Google Scholar
• Lan JS, Xie SS, Li SY, et al. Design, synthesis and evaluation of novel tacrin-(β-carboline) hybrids as multifunctional agents for the treatment of Alzheimer’s disease. Bioorg Med Chem 2014;22:6089–104.
   PubMed Web of Science ®Google Scholar
• Fleck C, Appenroth D, Fang L, et al. Investigation into the in vivo effects of five novel tacrine/ferulic acid and β-carboline derivatives on scopolamine-induced cognitive impairment in rats using radial maze paradigm. Arzneimittelforschung 2010;60:299–306.
   PubMed Web of Science ®Google Scholar
• Univ Sun Yat Sen. Tacrine-caffeic acid hetero-blends, their preparation method and medicinal compositions. CN102617465;2012.
   Google Scholar
• Univ Sun Yat Sen. Tacrine-ferulaic acid hetero-blend, preparation method and pharmaceutical compositions thereof. CN101284812;2008.
   Google Scholar
• Chao X, He X, Yang Y, et al. Design, synthesis and pharmacological evaluation of novel tacrine-caffeic acid hybrids as multi-targeted compounds against Alzheimer’s disease. Bioorg Med Chem Lett 2012;22:6498–6502.
   PubMed Web of Science ®Google Scholar
• Univ Hefei Technology. Tacrine-phenothiazine isodiad compound and preparation method thereof. CN102936244;2013.
   Google Scholar
• Hui AL, Chen Y, Zhu SJ, et al. Design and synthesis of tacrine-phenothiazine hybrids as multitarget drugs for Alzheimer’s disease. Med Chem Res 2014;23:3546–3557.
   Web of Science ®Google Scholar
• Rosini M, Andrisano V, Bartolini M, et al. Rational approach to discover multipotent anti-Alzheimer drugs. J Med Chem 2005;48:360–363.
   PubMed Web of Science ®Google Scholar
• Univ Huazhong Science Tech. Sulfydryl-containing tacrine derivative and preparation method and application thereof. CN102391180;2012.
   Google Scholar
• Keri RS, Quintanova C, Marques SM, et al. Design, synthesis and neuroprotective evaluation of novel tacrine-benzothiazole hybrids as multi-targeted compounds against Alzheimer’s disease. Bioorg Med Chem 2013;21:4559–4569.
   PubMed Web of Science ®Google Scholar
• Lannfelt L, Blennow K, Zetterberg H, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomized, placebo-controlled trial. Lancet Neurol 2008;7:779–786.
   PubMed Web of Science ®Google Scholar
• Fernandez-Bachiller MI, Perez C, Gonzalez-Munoz GC, et al. Novel Tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer’s disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. J Med Chem 2010;53:4927–4937.
   PubMed Web of Science ®Google Scholar
• Univ Southeast. Deferasirox-tacrine metal ion chelating agent and pharmaceutical use thereof. CN104817538;2015.
   Google Scholar
• Kochi A, Eckroat T, Green KD, et al. A novel hybrid of 6-chlorotacrine and metal-amyloid-β modulator for inhibition of acetylcholinesterase and metal-induced amyloid-β aggregation. Chem Sci 2013;4:4137–4145.
   Web of Science ®Google Scholar
• Nimmrich V, Eckert A. Calcium channel blockers and dementia. Brit J Pharmacol 2013;169:1203–1210.
   PubMed Web of Science ®Google Scholar
• Jiangsu Simcere Pharmaceutical. Hydrogenated acridine derivative and application thereof. CN103524413;2014.
   Google Scholar
• Chen R, Feng L, Zhang Z, et al. 1,4-dihydro-naphthyridine derivative and pharmaceutical composition and use thereof. US20140364443;2014.
   Google Scholar
• Jiangsu Simcere Pharmaceutical. 5-amino-1,4-dihydro-1,8-naphthyridine derivative and pharmaceutical composition and use thereof. WO2013152704;2013.
   Google Scholar
• Jiangsu Simcere Pharmaceutical. Compounds and uses as L-type calcium channel blocker and/or acetylcholinesterase inhibitor thereof. WO2012065527;2012.
   Google Scholar
• Marco-Contelles J, Leon R, de los Rios C, et al. Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer’s disease. J Med Chem 2009;52:2724–2732.
   PubMed Web of Science ®Google Scholar
• De los Rios C, Egea J, Marco-Contelles J, et al. Synthesis, inhibitory activity of cholinesterase, and neuroprotective profile of novel 1,8-naphthyridine derivatives. J Med Chem 2010;53:5129–5143.
   PubMed Web of Science ®Google Scholar
• Chen Y, Sun J, Fang L, et al. Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors. J Med Chem 2012;55:4309–4321.
   PubMed Web of Science ®Google Scholar
• Chen Y, Sun J, Huang Z, et al. Design, synthesis and evaluation of tacrine-flurbiprofen-nitrate trihybrids as novel anti-Alzheimer’s disease agents. Bioorg Med Chem 2013;21:2462–2470.
   PubMed Web of Science ®Google Scholar
• Xie SS, Wang XB, Li JY, et al. Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer’s disease. Eur J Med Chem 2013;64:540–553.
   PubMed Web of Science ®Google Scholar
• Hamulakova S, Janovec L, Hrabinova M, et al. Synthesis and biological evaluation of novel tacrine derivatives and tacrine-coumarin hybrids as cholinesterase inhibitors. J Med Chem 2014;57:7073–7084.
   PubMed Web of Science ®Google Scholar
• Li SY, Wang XB, Xie SS, et al. Multifunctional tacrine-flavonoid hybrids with cholinergic, β-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer’s disease. Eur J Med Chem 2013;69:632–646.
   PubMed Web of Science ®Google Scholar
• Fernandez-Bachiller MI, Perez C, Monjas L, et al. New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer’s disease, with cholinergic, antioxidant, and βα reducing properties. J Med Chem 2012;55:1303–1317.
   PubMed Web of Science ®Google Scholar
• Zhejiang University. 2-methoxyphenyl-dimethylamino formic ether derivative and preparation method and application thereof. CN103420941;2013.
   Google Scholar
• Ak T, Gulcin I. Antioxidant and radical scavenging properties of curcumin. Chem-Biol Interact 2008;174:27–37.
   PubMed Web of Science ®Google Scholar
• Li Y, Peng P, Tang L, et al. Design, synthesis and evaluation of rivastigmine and curcumin hybrids as site-activated multitarget-directed ligands for Alzheimer’s disease therapy, Bioorg Med Chem 2014;22:4717–4725.
   PubMed Web of Science ®Google Scholar
• Universite de Rouen. 7,11-methanocycloocta[B]Quinoline derivative as highly functionalizable acetylcholinesterase inhibitors. US20150197735;2015.
   Google Scholar
• Perioli L, Ambrogi V, Bernardini C, et al. Potential prodrugs of non-steroidal anti-inflammatory agents for targeted drug delivery to the CNS. Eur J Med Chem 2004;39:715–727.
   PubMed Web of Science ®Google Scholar
• Lovestone S, Boada M, Dubois B, et al. A phase II trial of tideglusib in Alzheimer’s disease. J Alzheimers Dis 2015;45:75–88.
   PubMed Web of Science ®Google Scholar
• Jiangsu Simovay Pharmaceutical Co. 1,2,4-thiadiazole-3,5-dione derivatives, and pharmaceutical composition and application thereof. CN103992312;2014.
   Google Scholar
• Huaihai Inst Technology. Amino sugar thiazole derivative as well as synthetic method and application thereof. CN104292280;2015.
   Google Scholar
• Pakaski M, Kalman J. Interactions between the amyloid and ccholinergic mechanisms in Azlheimer’s disease. Neurochem Int 2008;103–11.
   PubMed Web of Science ®Google Scholar
• Huang W, Tang L, Hu Yongzhou, et al. Searching for the multi-target-directed ligands against Alzheimer’s disease: discovery of quinoxaline-based hybrid compounds with AChE, H₃R and BACE1 inhibitory activities. Bioorg Med Chem 2011;23:7158–7167.
   Web of Science ®Google Scholar
• Kunming Inst Botany CN ACAD. Pyrrolidone compounds as well as medical composition and application thereof. CN104800209;2015.
   Google Scholar
• ISIS Innovation. Immunogenic composition. WO2009150433;2009.
   Google Scholar
• Cui L, Wang Y, Xu J, et al. Discovering new acetylcholinesterase inhibitors by mining the Buzhongyiqi Decoction recipe data. J Chem Inf Model 2015;55:2455–2463.
   PubMed Web of Science ®Google Scholar
• Univ Guangzhou Chinese Medicine. Application of 2-phenyl-benzo-five membered heterocycle compound and derivative of 2-phenyl-benzo-five-membered heterocycle compound. CN104829569;2015.
   Google Scholar
• Hangzhou Zhongmei Huadong Pharmaceutical Co LTD. 2-aminothiazole derivatives and methods of preparing and using the same. US2014004155;2014.
   Google Scholar
• Srosznajder J, Czapski G, Strosznajder R, et al. Poly(ADP-ribose) polymerase-1 in amyloid beta toxicity and Alzheimer’s diease. Mol Neurobiol 2012;46:78–84.
   PubMed Web of Science ®Google Scholar
• Goll Y, Bekenstein U, Soreq H, et al. Sustained Alzheimer’s amyloid pathology in myeloid differentiation protein-88-deficient APPswe/PS1 mice. Neurodegener Dis 2014;13:58–60.
   PubMed Web of Science ®Google Scholar
• Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H₃) of histamine receptor. Nature 1983;302:832–837.
   PubMed Web of Science ®Google Scholar
• Esbenshade TA, Browman KE, Brioni JD, et al. The histamine H₃ receptor: an attractive target for the treatment of cognitive disorders. Brit J Pharmacol 2008;154;1166–81.
   PubMed Web of Science ®Google Scholar
• Richter Gedeon Nyrt. H₃ antagonists containing phenoxypiperidine core structure. US20160009645;2014.
   Google Scholar
• Lai DH, Yang ZD, Xue WW, et al. Isolation, characterization and acetylcholinesterase inhibitory activity from roots of Stemona sessilifolia. Fitoterapia 2013;89:257–264.
   PubMed Web of Science ®Google Scholar
• Univ Lanzhou Tech. Stemona root alkaloid monomer components and applications thereof. CN103387580;2013.
   Google Scholar
• Inst Materia Medica Cams. Clavatine A-C and preparation method as well as pharmaceutical composition and application thereof. CN103059043;2013.
   Google Scholar
• Wang XJ, Zhang GJ, Zhuang PY, et al. Lycojaponicumins A-C, Three Alkaloids with an Unprecedented Skeleton from Lycopodium japonicum. Org Lett 2012;14:2614–2617.
   PubMed Web of Science ®Google Scholar
• Cao ZF, Yang P, Zhou QS. Multiple biological functions and pharmacological effects of lycorine. Sci China Chem 2013;56:1382–1391.
   PubMed Web of Science ®Google Scholar
• McNulty J, Nair J, Little J, et al. Structure-activity studies on acetylcholinesterase inhibition in the lycorine series of Amaryllidaceae alkaloids. Bioorg Med Chem Lett 2010;20:5290–5294.
   PubMed Web of Science ®Google Scholar
• Wang YH, Wan QL, Gu CD, et al. Synthesis and biological evaluation of lycorine derivatives as dual inhibitors of human acetylcholinesterase and butyrylcholinesterase. Chem Cent J 2012;6:96.
   PubMed Web of Science ®Google Scholar
• Kunming Inst Botany CN ACAD. Compound 1,10-N-decylene lycorine dibromo salt, pharmaceutical composition and application thereof in medicine. CN102746325;2012.
   Google Scholar
• Harborne JB, Baxter H, Moss GD. Phytochemical Dictionary: A Handbook of Bioactive Compounds from Plants. 2nd ed; 1999.
   Google Scholar
• He K, Du J. Two new steroidal alkaloids from the roots of Sarcococca ruscifolia. J Asian Nat Prod Res 2010;12:233–238.
   PubMed Web of Science ®Google Scholar
• Guiyang College Traditional Chinese Medicine. Use of 20alpha-dimethylamino-2alpha-hydroxy-3beta-tiropramide-5alpha-pregnane. CN102813659;2012.
   Google Scholar
• Univ Shenyang Chemical Tech. Triterpene compounds with acetylcholinesterase inhibition activity, and preparation method thereof. CN104788525;2015.
   Google Scholar
• Univ Guangzhou Chinese Medicine. Coumarone derivative, and preparation method and applications thereof. CN103333163;2013.
   Google Scholar
• University of Iowa Research Foundation. Compounds and methods to treat organophosphorus poisoning. US20140323473;2014.
   Google Scholar
• Mississippi State University, Phenoxyalkyl pyridinium oxime therapeutics for treatment of organophosphate poisoning. US 9227937; 2016..
   Google Scholar
• Southwest Res Inst. Reactivators of organophosphorous inhibited acetylcholinesterase. US20140350262;2014.
   Google Scholar
• McHardy SF, Bohmann JA, Corbett MR, et al. Design, synthesis, and characterization of novel, nonquaternary reactivators of GF-induced human acetylcholinesterase. Bioorg Med Chem Lett 2014;24:1711–1714.
   PubMed Web of Science ®Google Scholar
• Southwest Res Inst. Oximes for the treatment of peripheral and central nervous system exposure to acetyl cholinesterase inhibitors. US20150005328;2015.
   Google Scholar
• Univ California, Scripps Research Inst. Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them. US20150361060;2015.
   Google Scholar
• Radic Z, Sharpless B, Taylor P, et al. Refinement of structural leads for centerally acting oxime reactivators of phosphylated cholinesterases. J Bio Chem 2012;287:11798–11809.
   PubMed Web of Science ®Google Scholar
• Sit R, Sharpless B, Taylor P, et al. New structural leads for centrally acting oxime reactivators of phosphylated cholinesterases. J Bio Chem 2011;286:19422–19430.
   PubMed Web of Science ®Google Scholar
• Human Biomolecular Research Institute. Blood brain barrier-penetrating oximes for cholistenerases reactivation. WO2012083261; 2012.
   Google Scholar
• Okolotowicz KJ, Dwyer M, Smith E, et al. Preclinical studies of noncharged oxime reactivators for organophosphate exposure. J. Biochem Molecular Toxicology. 2014;28:23–32.
   PubMed Web of Science ®Google Scholar
• Universite de Strasbourg, Fr.; Commissariat a l'Energie Atomique et aux Energies Alternatives; Centre National de la Recherche Scientifique; Universite de Rouen; L'Etat Francais (Ministere de la Defense) Represente par le Directeur de l'Institut de Recherche Biomedicale des Armees. Pyridine derivatives as uncharged reactivators of human acetylcholinesterase and their preparation and use for the treatment of nervous and respiratory failure. WO 2015075082; 2015.
   Google Scholar
• The Trustees Of Columbia University In The City Of New York. Activation or reactivation of AChE. WO2014210168; 2014.
   Google Scholar
• Katz FS, Pecic S, Tran TH, et al. Discovery of new classes of compounds that reactivate acetylcholinesterase inhibited by organophosphates. Chembiochem: A European Journal Of Chemical Biology. 2015;16(15):2205–2215.
   PubMed Web of Science ®Google Scholar
• Shih T-M, Koplovitz I, Kan RK, et al. In Search of an Effective in vivo Reactivator for Organophosphorus Nerve Agent-Inhibited Acetylcholinesterase in the Central Nervous System. Aip Studies Bio 2012;4:451–478.
   Google Scholar
• Ghavre M, Froese J, Pour M, et al. Synthesis of Amaryllidaceae Constituents and Unnatural Derivatives. Angew Chem Int Ed 2016;55:2–52.
   Web of Science ®Google Scholar
• Eyer P, Hagedorn I, Ladstetter B, Study on the stability of the oxime HI 6 in aqueous solution. Arch Toxicol 1988;62:224–226.
   PubMed Web of Science ®Google Scholar
• Clark APZ, Dixon H, Cantu NL, et al. Good Manufacturing Practice: Manufacturing of a Nerve Agent Antidote Nanoparticle Suspension. Int J Toxicol 2013;32:18S–29S.
   Google Scholar